AnilKChandrakerMD
Nephrology • Worcester, MAKidney & Pancreas Transplantation
Associate Professor, Medicine, Harvard Medical School
Dr. Chandraker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Lake Ave N
Worcester, MA 01655Phone+1 508-334-3155
Education & Training
Brigham and Women's Hospital/Massachusetts General HospitalFellowship, Nephrology, 1995 - 1999
University of Glasgow Faculty of MedicineClass of 1987
Certifications & Licensure
MA State Medical License 1999 - 2026
Awards, Honors, & Recognition
- President American Society of Transplantation, 2016-2017
- Fellow (ASNF) American Society of Nephrology
Clinical Trials
- Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Start of enrollment: 2006 Mar 01
- BK Treatment Study Start of enrollment: 2009 Feb 01
- Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation Start of enrollment: 2011 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 13 citationsCemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.Glenn J Hanna, Harita Dharanesswaran, Anita Giobbie-Hurder, John J Harran, Zixi Liao
Journal of Clinical Oncology. 2024-03-20 - 48 citationsT-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen.Anil Chandraker, Mary E. Russell, Troels Glysing-Jensen, Theresa Willett, Mohamed H. Sayegh
Transplantation. 1997-04-27 - 78 citationsAcute rejection in vascularized composite allotransplantation.Sebastian Fischer, Christine G. Lian, Maximilian Kueckelhaus, Terry B. Strom, Elazer R. Edelman
Current Opinion in Organ Transplantation. 2014-12-01
Press Mentions
AlloVir Reports Full-Year 2022 Financial Results and 2023 OutlookFebruary 17th, 2023- AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant RecipientsJune 7th, 2022
- Two Brigham Scientists Honored for Their Work on Gene and Cell TherapiesMay 9th, 2022
- Join now to see all
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
